NEW CANAAN, CT, October 27, 2003—The Sabin Vaccine Institute announced the appointment of Nathan Tinker, PhD, as executive director of the Cancer Vaccine Consortium (CVC), a new initiative of the decade- old New Canaan-based non-profit organization. Dr. Tinker, a resident of Norwalk, will be the principal organizer of the Consortium program, which works with a growing list of biopharmaceutical companies to advance discovery of new therapies for a range of cancers. Dr. Tinker brings to the Institute and the CVC a broad and distinguished range of experience from both academia and the business sector.

“Dr. Tinker’s background and experience in building technology networks will be a great asset in developing the scope and mission of the Cancer Vaccine Consortium, and in expanding the organization’s membership,” said H.R. Shepherd, DSc, chairman of the Sabin Vaccine Institute. “We are counting on his astute leadership of this undertaking, which can be a great asset for progress towards new avenues of therapy in vaccine treatments of cancer.”

As executive director of the Cancer Vaccine Consortium, Dr. Tinker will guide the Consortium’s programming and administration, including policy analysis, member services and fund raising efforts. “The Cancer Vaccine Consortium will be a vital element in the ongoing war against cancer,” said Dr. Tinker. “I am proud to be a part of this important endeavor.”

Dr. Tinker is an experienced senior executive with management and leadership expertise with biotechnology and nanotechnology companies, Internet and telecommunications technology companies, and public relations and marketing businesses. An accomplished businessman and academic with more than a decade of business leadership experience, he has helped launch more than 12 high-technology companies. He is also a founder of the NanoBusiness Alliance, a non-profit trade association of nanotechnology organizations and holds a PhD from Fordham University in New York.

The Cancer Vaccine Consortium comprises some 20 organizations with an interest in the development of vaccines and immunotherapies for cancer. The goal of the consortium is to accelerate the process of bringing cancer vaccines from the development stage to the clinic.

For more information about the Cancer Vaccine Consortium, visit www.sabin.orgor contact Nathan Tinker, [email protected], 203-972-7907.

EDITOR’s NOTE: A scanned photograph of Dr. Tinker accompanies this release and is in jpg format.

The mission of the Albert B. Sabin Vaccine Institute is to save lives by stimulating development of new vaccines and increasing immunization rates throughout the world. Founded in 1993, the Institute pursues Dr. Albert Sabin’s vision of a world protected from disease by vaccines. Sabin Institute colloquia convene leaders in academia, government, industry, and philanthropy to explore solutions to problems in vaccine research and development, and promote dialogue to prevent infectious diseases and treat cancer. As an immunization advocate, it helps policy makers shape sound public health policies and informs the public about the importance of vaccinations. The Sabin Institute’s Hookworm Vaccine Initiative is working to develop a vaccine to prevent an infection that afflicts more than one billion individuals, and is a leading cause of anemia and malnutrition in the developing world.